Literature DB >> 18497546

Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines.

Min Jung Kim1, June-Chul Lee, Jae-Jung Lee, Soyeon Kim, Sang Goo Lee, Seok-Woo Park, Myung Whun Sung, Dae Seog Heo.   

Abstract

OBJECTIVE: Integrin-associated protein (CD47) binds specifically to the inhibitory receptor signal-regulatory protein. This study was designed to evaluate the role of CD47 in natural killer (NK) cell-mediated cytotoxicity against cancer cells.
METHODS: Head-and-neck squamous cell carcinoma (HNSCC) cell lines were analyzed for the expression of CD47 and susceptibility to NK cell-mediated killing. Cytolytic activity was assessed by (51)Cr-specific release assays and by measuring cytokine production.
RESULTS: HNSCC cell lines that had high CD47 expression showed lower levels of NK cytotoxicity than those with low CD47 expression. After pre-treating cells with neutralizing major histocompatibility complex (MHC) class I or anti-CD47 antibodies, NK cell-mediated cytotoxicity against HNSCC cell lines increased. In addition, when CD47 cDNA was transfected into Caco-2 cells, NK cell-mediated cytotoxicity decreased.
CONCLUSION: These findings suggest that CD47 may play an inhibitory role in NK cell-mediated cytotoxicity against cancer cells, implying a possible mechanism of immune escape in human cancer. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497546     DOI: 10.1159/000132568

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  57 in total

Review 1.  Macrophages as mediators of tumor immunosurveillance.

Authors:  Siddhartha Jaiswal; Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Trends Immunol       Date:  2010-05-07       Impact factor: 16.687

Review 2.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.

Authors:  E Sick; A Jeanne; C Schneider; S Dedieu; K Takeda; L Martiny
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 3.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.

Authors:  Mark P Chao; Irving L Weissman; Ravindra Majeti
Journal:  Curr Opin Immunol       Date:  2012-02-04       Impact factor: 7.486

Review 4.  Next generation immune-checkpoints for cancer therapy.

Authors:  Chiara Donini; Lorenzo D'Ambrosio; Giovanni Grignani; Massimo Aglietta; Dario Sangiolo
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

5.  Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.

Authors:  Pulak Ranjan Nath; Dipasmita Pal-Nath; Ajeet Mandal; Margaret C Cam; Anthony L Schwartz; David D Roberts
Journal:  Cancer Immunol Res       Date:  2019-07-30       Impact factor: 11.151

Review 6.  CD47: a new player in phagocytosis and xenograft rejection.

Authors:  Nalu Navarro-Alvarez; Yong-Guang Yang
Journal:  Cell Mol Immunol       Date:  2011-01-24       Impact factor: 11.530

Review 7.  CD47: role in the immune system and application to cancer therapy.

Authors:  Seyed Mohammad Gheibi Hayat; Vanessa Bianconi; Matteo Pirro; Mahmoud R Jaafari; Mahdi Hatamipour; Amirhossein Sahebkar
Journal:  Cell Oncol (Dordr)       Date:  2019-08-14       Impact factor: 6.730

8.  Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.

Authors:  Kipp Weiskopf; Katie L Anderson; Daisuke Ito; Peter J Schnorr; Hirotaka Tomiyasu; Aaron M Ring; Kristin Bloink; Jem Efe; Sarah Rue; David Lowery; Amira Barkal; Susan Prohaska; Kelly M McKenna; Ingrid Cornax; Timothy D O'Brien; M Gerard O'Sullivan; Irving L Weissman; Jaime F Modiano
Journal:  Cancer Immunol Res       Date:  2016-11-14       Impact factor: 11.151

9.  Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma.

Authors:  Lei Wu; Guang-Tao Yu; Wei-Wei Deng; Liang Mao; Lei-Lei Yang; Si-Rui Ma; Lin-Lin Bu; Ashok B Kulkarni; Wen-Feng Zhang; Lu Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

10.  Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.

Authors:  Albin Jeanne; Camille Boulagnon-Rombi; Jérôme Devy; Louis Théret; Caroline Fichel; Nicole Bouland; Marie-Danièle Diebold; Laurent Martiny; Christophe Schneider; Stéphane Dedieu
Journal:  Clin Exp Metastasis       Date:  2016-06-27       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.